文献速递血栓与止血

口服全反式维甲酸联合达那唑对比达那唑单药作为成人原发性免疫性血小板减少症二线治疗:多中心、随机、开放标签、2期试验

Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2017-09-13

这项在中国五家三级医疗中心进行的多中心、随机、开放标签、2期试验,纳入96例非脾切除、对糖皮质激素耐药或复发、血小板计数低于30×10⁹/L的成人原发性免疫性血小板减少症患者,1:1随机分配接受口服全反式维甲酸(10 mg每日两次)联合达那唑(200 mg每日两次)或达那唑单药(200 mg每日两次)治疗16周。主要终点12个月持续缓解率在联合组为62%(28/45),达那唑单药组为25%(12/48),比值比4.94(95%CI 2.03-12.02,p=0.00037)。仅报告2例3级不良事件,无4级或更严重不良事件或治疗相关死亡。

要点

  • ATRA联合达那唑组12个月持续缓解率为62%(28/45),达那唑单药组为25%(12/48),比值比4.94(95%CI 2.03-12.02,p=0.00037)。
  • ATRA联合达那唑组报告1例(2%)3级不良事件为皮肤干燥,达那唑单药组报告1例(2%)3级不良事件为肝损伤。
  • 两组均无4级或更严重不良事件或治疗相关死亡。

核心结论

  • 接受全反式维甲酸联合达那唑治疗的原发性免疫性血小板减少症患者相比达那唑单药治疗获得了快速且持续的缓解。
  • 该发现提示全反式维甲酸是对糖皮质激素耐药或复发的原发性免疫性血小板减少症患者有前景的候选治疗。

研究设计与样本

  • 多中心、随机、开放标签、2期研究,在中国五家不同三级医疗中心进行。
  • 纳入成人(≥18岁)原发性免疫性血小板减少症患者,为非脾切除、对糖皮质激素治疗耐药或复发、血小板计数低于30×10⁹/L。
  • 设盲统计师采用简单随机化按1:1将患者分配至口服全反式维甲酸(10 mg每日两次)联合口服达那唑(200 mg每日两次)组或口服达那唑单药(200 mg每日两次)组,治疗16周。
  • 2012年6月1日至2016年7月1日筛查130例患者,排除34例,随机分配96例;改良意向治疗分析纳入93例(联合组45例,达那唑组48例)。
  • 研究因试验结果跨过持续缓解的期中分析疗效边界而提前停止入组。

主要发现

  • 12个月随访时,全反式维甲酸联合达那唑组持续缓解率高于达那唑单药组(28/45[62%] vs 12/48[25%];比值比4.94,95%CI 2.03-12.02,p=0.00037)。
  • 仅报告2例3级不良事件:全反式维甲酸联合达那唑组1例(2%)皮肤干燥,达那唑单药组1例(2%)肝损伤。
  • 两组均无4级或更严重不良事件或治疗相关死亡。

关键数值与推荐

  • 主要终点为12个月持续缓解,定义为随访12个月时血小板计数≥30×10⁹/L且至少为基线血小板计数的两倍(部分缓解),或血小板计数≥100×10⁹/L(完全缓解),且无出血、未使用挽救治疗。

临床怎么用

  • 原文结论指出全反式维甲酸联合达那唑相比达那唑单药使患者获得快速且持续的缓解,并认为全反式维甲酸是对糖皮质激素耐药或复发的原发性免疫性血小板减少症患者有前景的候选治疗。

局限性

  • 研究因试验结果跨过持续缓解的期中分析疗效边界而提前停止入组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary immune thrombocytopenia is a severe bleeding disorder. About 50-85% of patients achieve initial remission from first-line therapies, but optimal second-line treatment remains a challenge. All-trans retinoic acid (ATRA) has an immunomodulatory effect on haemopoiesis, making it a possible treatment option. We aimed to evaluate the efficacy and safety of ATRA plus danazol versus danazol in non-splenectomised patients with corticosteroid-resistant or relapsed primary immune thrombocytopenia. METHODS: We did a multicentre, randomised, open-label, phase 2 study of adult patients (≥18 years) with primary immune thrombocytopenia from five different tertiary medical centres in China. Those eligible were non-splenectomised, resistant to corticosteroid treatment or relapsed, and had a platelet count less than 30 × 109 per L. Masked statisticians used simple randomisation to assign patients (1:1) to receive oral ATRA (10 mg twice daily) plus oral danazol (200 mg twice daily) or oral danazol monotherapy (200 mg twice daily) for 16 weeks. Neither clinicians nor patients were masked to group assignments. All patients were assessed every week during the first 8 weeks of treatment, and at 2-week intervals thereafter. The primary endpoint was 12-month sustained response defined as platelet count of 30 × 109 per L or more and at least a doubling of baseline platelet count (partial response), or a platelet count of 100 × 109 per L or more (complete response) and the absence of bleeding without rescue medication at the 12-month follow-up. All randomly allocated patients, except for those who withdrew consent, were included in the modified intention-to-treat population and efficacy assessment, and all patients who received at least one dose of the study agents were included in the safety analysis. Study enrolment was stopped early because the trial results crossed the interim analysis efficacy boundary for sustained response. This trial is registered with ClinicalTrials.gov, number NCT01667263. FINDINGS: From June 1, 2012, to July 1, 2016, we screened 130 patients for eligibility; 34 were excluded and 96 were randomly assigned. 93 patients were included in the modified intention-to-treat analysis: 45 in the ATRA plus danazol group and 48 in the danazol group. At the 12-month follow-up, sustained response was achieved more frequently in patients receiving ATRA plus danazol than in those receiving danazol monotherapy (28 [62%] of 45 vs 12 [25%] of 48; odds ratio 4·94, 95% CI 2·03-12·02, p=0·00037). Only two grade 3 adverse events were reported: one (2%) patient receiving ATRA plus danazol with dry skin, and one (2%) patient receiving danazol monotherapy with liver injury. There was no grade 4 or worse adverse event or treatment-related death in either group. INTERPRETATION: Patients with primary immune thrombocytopenia given ATRA plus danazol had a rapid and sustained response compared with danazol monotherapy. This finding suggests that ATRA represents a promising candidate for patients with corticosteroid-resistant or relapsed primary immune thrombocytopenia. FUNDING: National Natural Science Foundation of China, Beijing Natural Science Foundation, Beijing Municipal Science and Technology Commission, and the National Key Research and Development Program of China.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Feng FE, Feng R, Wang M, et al. Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. Lancet Haematol. 2017. PMID: 28917657. doi:10.1016/S2352-3026(17)30170-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。